PharmAsia News takes a closer look at presentations by Abbott, Amgen, Medtronic, Mylan, Shire, Stryker and Valeant.
In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the annual JP Morgan Global Healthcare Conference in San Francisco ([A#28130113001]).
For this profile, we zoom in on the 34th annual Goldman Sach's Global Health Care Conference, held June 11-13 in...
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
Multi-blockbuster falls short in a giant cell arteritis study.
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
